Gene Discovery in CHB Patients to Identify Unknown Pathways That Lead to B and NK Cell Deregulation

Recruiting N/A Interventional Study
Chronic Hepatitis B Virus
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Basic Science
Participants needed
140 (estimated)
Sponsor
University Hospital, Limoges · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Natural Killer (NK) and B cell immune responses occur during the early stages of infection and are essential to eradicate it. Yet, chronic hepatitis B (CHB) infection occurs because the antiviral immune response is insufficient. In both NK and B cell studies we will explore the genetic alterations that occur during the varied chronic stages of the disease. We believe that our findings will allow u…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Male or female, age ≥18 years old * HBV infection or chronic HBV infection untreated or treated with a nucleoside or nucleotide analog * Willing and able to provide written informed consent * Affiliated with a social securityregimen Healthy volunteer must meet all of the foll…
Contacts

Paul CARRIER, MD

+335 55 05 80 22

paul.carrier@chu-limoges.fr

CONTACT